research High Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata
Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.
Search
for
Sort by
Research
210-240 / 1000+ results
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research Pharmacological Treatment of Alopecia
Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
research Alopecia Areata and Alopecia Areata Incognita
Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.
research One of the Best Treatments for Alopecia Areata Remains Unpublished
DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
research Efficacy of Oral Tofacitinib in the Treatment of Lichen Planopilaris
Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
research Molecular Correlation With Clinical Outcomes in an Open Label Clinical Trial of Oral Tofacitinib in Patients With Alopecia Areata
Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
research Efficacy of Tofacitinib in Pediatric Alopecia Universalis
Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
research New Modalities in the Treatment of Refractory Alopecia Areata
New treatments focusing on immune pathways show promise for stubborn hair loss.
research Using Artificial Intelligence to Analyze Publicly Available Social Media Posts to Understand Patient Perspectives Toward Specific Treatments of Alopecia Areata
Patients generally feel positive about alopecia areata treatments, but emotions vary by treatment type.
research Trachyonychia Secondary to Pediatric Alopecia Areata Responding to Oral Tofacitinib Therapy: A Case Report and Review of Literature
Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
research Unexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights
Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
research Efficacy of Baricitinib Compared to Conventional Therapy for Alopecia Areata
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
research Recalcitrant Lichen Planopilaris Treated with Upadacitinib: A Case Series
Upadacitinib may effectively treat resistant lichen planopilaris.
research Baricitinib as a Treatment for Myasthenia Gravis: A Case Report
Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
research A Case of Vitiligo Combined With Systemic Lupus Erythematosus Treated With Tofacitinib
Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Dupilumab Therapy for Alopecia Areata in a 4-Year-Old Patient Resistant to Baricitinib
Dupilumab helped a 4-year-old grow hair back after another treatment failed.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata
Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
research Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
research Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
research Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
research Baricitinib For Alopecia Areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research New Treatment Options For Alopecia Areata
Baricitinib is a new, effective treatment for advanced alopecia areata but is costly and has risks.